Substituted pyrazolo [3,4-d]pyrimidines as cytokine modulators
Provided are bicyclic heterocycle-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.
1. A compound of formula
wherein
R 1 is methyl,
R 2 is hydrogen,
n is 0, 1 or 2,
R 3 is cyclopropyl,
X 1 is a single bond or alkylene,
A, X 2 and D are a pyrazolopyrimidine group of formula III
k is an integer from 0 to 4,
w is an integer from 0 to 4,
R 13 is hydrogen, alkyl, OH or NH 2 , and
(CR 9 R 10 ) w E is alkyl, alkoxy, halo, —CH 2 -heterocyclyl, —CONH-cycloalkyl, alkylsulfonyl, alkylthio, alkylsulfonylamino, haloalkyl, aminocarbonyl, pseudohalo or heterocyclyl, or two (CR 9 R 10 ) w E groups, which substitute adjacent atoms on D, together form alkylenedioxy,
wherein
alkyl is lower alkyl having 1 to 6 carbon atoms,
alkylene is lower alkylene having 1 to 6 carbons,
haloalkyl is an alkyl group in which one or more of the hydrogen atoms are replaced by halogen
cycloalkyl is to a saturated mono- or multicyclic ring system of 3 to 10 carbon atoms,
alkoxy is RO—,
alkylthio is RS—,
R is lower alkyl having 1 to 6 carbon atoms
pseudohalo is cyanide, cyanate, thiocyanate, selenocyanate, trifluoromethoxy, or azido and
heterocyclyl is a monocyclic or multicyctic non-aromatic ring system of 3 to 10 members where 1 to 3, of the atoms in the ring system is a heteroatom selected from nitrogen, oxygen or sulfur or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , wherein X 1 is a single bond.
3. The compound according to claim 1 , which is selected from the group consisting of:
N-Cyclopropyl-4-methyl-3-(4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)-benzamide,
N-Cyclopropyl-3-[4-(2-methoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide,
N-Cyclopropyl-3-[4-(4-methanesulfonyl-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide, N-Cyclopropyl-3-[4-(3.4-dimethoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide, N-Cyclopropyl-3-[4-(4--methoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide, N-Cyclopropyl-4-methyl-3-{4-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-pyrazolo[3,4-d]pyrimidin-1-yl}-benzamide,
N-Cyclopropyl-3-[4-(3-ethoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide,
N-Cyclopropyl-3-[4-(3-iodo-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide,
N-Cyclopropyl-3-[4-(3-methoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl-benzamide,
N-Cyclopropyl-3-(6-hydroxy-4-phenyl-pyrazolo[3,4-d]pyrimidin-1-yl)4-methyl-benzamide, and
N-Cyclopropyl-4-methyl-3-{4-[3-(4H-[1,2,4]triazol-3-yl)-phenyl]-pyrazolo[3,4-d]pyrimidin-1-yl}-benzamide.
4. The compound according to claim 1 in the form of a pharmaceutically acceptable salt.
5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.